Data monitoring committees and early stopping guidelines: The southwest oncology group experience
- 15 July 1994
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 13 (13-14) , 1391-1399
- https://doi.org/10.1002/sim.4780131314
Abstract
Data Monitoring Committees in the Southwest Oncology Group comprise the study leadership and the leadership of the Group, augmented by some outside representation. The early stopping guidelines used by these committees are explicit in each protocol, and can be characterized as specifying a few interim analyses at conservative statistical levels. We describe our ten years of experience with this system, and give examples of different trials which have stopped either for positive or negative results.Keywords
This publication has 13 references indexed in Scilit:
- The case against independent monitoring committeesStatistics in Medicine, 1994
- Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.Journal of Clinical Oncology, 1993
- Data monitoring committees for southwest oncology group clinical trialsStatistics in Medicine, 1993
- [Evaluating Therapeutic Interventions: Some Issues and Experiences]: CommentStatistical Science, 1992
- Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.Journal of Clinical Oncology, 1992
- Changing Frequency of Interim Analysis in Sequential MonitoringBiometrics, 1989
- Procedures for serial testing in censored survival dataPublished by Institute of Mathematical Statistics ,1982
- Repeated assessment of results in clinical trials of cancer treatmentThe British Journal of Radiology, 1971